JP6557240B2 - ヒト免疫不全ウイルス／後天性免疫不全症候群の治療 - Google Patents

ヒト免疫不全ウイルス／後天性免疫不全症候群の治療 Download PDF

Info

Publication number
JP6557240B2
JP6557240B2 JP2016545336A JP2016545336A JP6557240B2 JP 6557240 B2 JP6557240 B2 JP 6557240B2 JP 2016545336 A JP2016545336 A JP 2016545336A JP 2016545336 A JP2016545336 A JP 2016545336A JP 6557240 B2 JP6557240 B2 JP 6557240B2
Authority
JP
Japan
Prior art keywords
hiv
composition
ath1
cells
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016545336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502058A (ja
JP2017502058A5 (enExample
Inventor
マイケル ハー−ノイ
マイケル ハー−ノイ
Original Assignee
イミュノバティブ セラピーズ，リミテッド
イミュノバティブ セラピーズ，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノバティブ セラピーズ，リミテッド, イミュノバティブ セラピーズ，リミテッド filed Critical イミュノバティブ セラピーズ，リミテッド
Publication of JP2017502058A publication Critical patent/JP2017502058A/ja
Publication of JP2017502058A5 publication Critical patent/JP2017502058A5/ja
Application granted granted Critical
Publication of JP6557240B2 publication Critical patent/JP6557240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016545336A 2014-01-08 2015-01-08 ヒト免疫不全ウイルス／後天性免疫不全症候群の治療 Active JP6557240B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461924936P 2014-01-08 2014-01-08
US61/924,936 2014-01-08
PCT/US2015/010658 WO2015105999A1 (en) 2014-01-08 2015-01-08 Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome

Publications (3)

Publication Number Publication Date
JP2017502058A JP2017502058A (ja) 2017-01-19
JP2017502058A5 JP2017502058A5 (enExample) 2018-02-08
JP6557240B2 true JP6557240B2 (ja) 2019-08-07

Family

ID=53494410

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016545336A Active JP6557240B2 (ja) 2014-01-08 2015-01-08 ヒト免疫不全ウイルス／後天性免疫不全症候群の治療

Country Status (12)

Country Link
US (3) US10272143B2 (enExample)
EP (1) EP3091990B1 (enExample)
JP (1) JP6557240B2 (enExample)
KR (1) KR102503400B1 (enExample)
CN (1) CN105899219B (enExample)
AU (1) AU2015204770B2 (enExample)
BR (1) BR112016015736B1 (enExample)
CA (1) CA2936086C (enExample)
IL (1) IL246643B (enExample)
PH (1) PH12016501359A1 (enExample)
SG (2) SG10201908048QA (enExample)
WO (1) WO2015105999A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150305983A1 (en) * 2009-11-20 2015-10-29 The University Of Versailles Saint-Quentin-En- Yvelines Quadruple therapy useful for treating persons afflicted with the human immunodeficiency virus (hiv)
US20190069528A1 (en) * 2016-03-21 2019-03-07 The George Washington University Engineered human hookworms as a novel biodelivery system for vaccines and biologicals
CN111886249A (zh) * 2017-09-18 2020-11-03 西托戴恩股份有限公司 用于鉴定和治疗适合长期抗-ccr5剂治疗的hiv-1感染患者亚群的筛选方法
USD1001795S1 (en) 2019-10-01 2023-10-17 Microsoft Corporation Computing device

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
WO2000066141A2 (en) 1999-05-04 2000-11-09 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
US6579521B2 (en) 2000-10-20 2003-06-17 Chiron Corporation Methods of therapy for HIV infection
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
KR20070019635A (ko) * 2003-08-28 2007-02-15 더 임뮨 리스판스 코포레이션 면역원성 ｈｉｖ 조성물 및 이와 관련된 방법
OA13246A (en) 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
EP1749090B1 (en) 2004-03-01 2017-05-17 Immunovative Therapies, Ltd. Cell therapy formulation method and composition
US8043619B2 (en) * 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US9695397B2 (en) 2008-10-01 2017-07-04 Immunovative Therapies Ltd. Th1 vaccination priming for active immunotherapy
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
WO2010051521A1 (en) 2008-10-31 2010-05-06 Lentigen Corporation Cell therapy product for the treatment of hiv infection
WO2011077100A1 (en) * 2009-12-24 2011-06-30 Cipla Limited Antiretroviral composition
MX2012011189A (es) 2010-03-26 2013-02-07 Glaxosmithkline Biolog Sa Vacuna contra el virus e inmunodeficiencia humana.
AU2011240752B2 (en) * 2010-04-13 2016-07-28 Immunovative Therapies, Ltd. Methods and compositions for inhibition of Treg cells
WO2011130247A2 (en) 2010-04-14 2011-10-20 The Penn State Research Foundation Strategies for the transgenic manipulation of filamentous fungi

Also Published As

Publication number Publication date
US10729754B2 (en) 2020-08-04
EP3091990A4 (en) 2017-10-04
IL246643A0 (en) 2016-08-31
AU2015204770A1 (en) 2016-08-18
JP2017502058A (ja) 2017-01-19
WO2015105999A1 (en) 2015-07-16
EP3091990A1 (en) 2016-11-16
BR112016015736A2 (enExample) 2017-08-08
US20180200348A1 (en) 2018-07-19
PH12016501359A1 (en) 2016-08-22
EP3091990B1 (en) 2021-05-12
CA2936086A1 (en) 2015-07-16
CN105899219A (zh) 2016-08-24
AU2015204770B2 (en) 2020-07-02
SG10201908048QA (en) 2019-10-30
US20150190488A1 (en) 2015-07-09
IL246643B (en) 2020-02-27
US20200368334A1 (en) 2020-11-26
US10272143B2 (en) 2019-04-30
KR20160124096A (ko) 2016-10-26
CA2936086C (en) 2024-02-27
CN105899219B (zh) 2021-08-13
SG11201605440TA (en) 2016-08-30
BR112016015736B1 (pt) 2022-01-04
KR102503400B1 (ko) 2023-02-23

Similar Documents

Publication Publication Date Title
Migueles et al. Success and failure of the cellular immune response against HIV-1
TW201808998A (zh) 以cd4抗體於穩定接受haart治療的患者進行hiv感染的治療和持續性的病毒緩解
Mehraj et al. Immune suppression by myeloid cells in HIV infection: new targets for immunotherapy
US20200368334A1 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
JP2023041770A (ja) Ｇｐ１２０ ｖ３グリカン指向性抗体による療法に感受性であるｈｉｖ患者を同定する方法
Arenas et al. Recent advances in CD8+ T cell-based immune therapies for HIV cure
Van Gulck et al. Role of dendritic cells in HIV-immunotherapy
AU2021377614B2 (en) METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
TWI714529B (zh) 人類免疫缺乏病毒/後天性免疫缺乏症候群之治療
Calarota et al. Cellular HIV-1 immune responses in natural infection and after genetic immunization
HK1227297B (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
HK1227297A1 (en) Treatment of human immunodeficiency virus/acquired immunodeficiency syndrome
Board DESIGN AND DEVELOPMENT OF BISPECIFIC ANTIBODIES FOR HIV-1 RESERVOIR ELIMINATION
Toma´ sˇ Hanke and Andrew J. McMichael The Role of Cytotoxic T Lymphocytes in Protection Against HIV Infection and AIDS
Yager Natural and therapy-induced immune control of HIV-1
HK40127014A (en) Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
Starke SIV-Specific CD8+ T Cells are Phenotypically, Functionally, and Clonotypically Distinct Across Lymphoid and Mucosal Tissues
HK40119625A (en) Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies
HK40092948A (en) Methods of identifying hiv patients sensitive to therapy with gp120 cd4 binding site-directed antibodies
Abduljawad Optimizing a Universal Mosaic T cell vaccine for HIV-1
Cale Mechanisms used by simian immunodeficiency viruses to evade virus-specific CD8-positive T lymphocyte responses
Tabethe et al. Topics in
Garba et al. Cytotoxic T‐Cell (CTL) Function in HIV Infection

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190330

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190617

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190711

R150 Certificate of patent or registration of utility model

Ref document number: 6557240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250